4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Low-Grade Glioma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 193 ongoing clinical trials involving Low-Grade Glioma
Of the 193 trials,74 trials are in Phase II
Furthermore, 51 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Low-Grade Glioma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Low-Grade Glioma, an Oncology condition. The largest number of ongoing clinical trials for Low-Grade Glioma is conducted in North America. Europe and Asia-Pacific are among some of the other prominent regions engaged in Low-Grade Glioma-related drug trials.

National Cancer Institute US: The leading ongoing Low-Grade Glioma related clinical trial sponsor

National Cancer Institute US is the top sponsor for Low-Grade Glioma-related ongoing clinical trials.

Les Laboratoires Servier SAS, Children's Oncology Group, University of California San Francisco, Pediatric Brain Tumor Consortium, and Beijing Sanbo Brain Hospital are among other notable clinical trial sponsors involved in Low-Grade Glioma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Low-Grade Glioma

DCVax-L is the sole key marketed drug involving Low-Grade Glioma.

DCVax-L contains autologous, antigen-presenting dendritic cells. DCVax-L is a cancer vaccine consisting of lymphocytes harvested from a patient with cancer and induced to become antigen-presenting cells (APCs) known as dendritic cells. The dendritic cells are transduced with the gene encoding an antigen-specific to the patient's cancer and then returned to the patient. It is formulated as a suspension for an intradermal route of administration. DCVax-L is indicated for the adjuvant treatment of glioma brain cancers (both Glioblastoma multiforme and lower-grade gliomas) in adults after tumor resection and standard therapy (Chemo and or radiotherapy). DCVax-L was first approved in 2014 and is marketed in Germany by NW Biotherapeutics Gmbh.